Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
81.39(c) 79.88(c) 80.23(c) 81.31(c) 80.54(c) Last
1 115 563 814 430 904 037 756 211 920 663 Volume
+1.61% -1.86% +0.44% +1.35% -0.95% Change
More quotes
Financials (USD)
Sales 2019 2 075 M
EBIT 2019 297 M
Net income 2019 318 M
Finance 2019 1 774 M
Yield 2019 -
Sales 2020 2 385 M
EBIT 2020 509 M
Net income 2020 448 M
Finance 2020 2 351 M
Yield 2020 -
P/E ratio 2019 56,0x
P/E ratio 2020 39,2x
EV / Sales2019 7,47x
EV / Sales2020 6,26x
Capitalization 17 271 M
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (77.9%); - royalties (12.5%); - income from research and... 
Sector
Biotechnology & Medical Research
Calendar
07/30 | 07:00amEarnings Release
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
07/11INCYTE : Summary ToggleIncyte to Report Second Quarter Financial Results
PU
07/11INCYTE : to Report Second Quarter Financial Results
BU
07/02INCYTE : Summary ToggleIncyte and Zai Lab Announce Collaboration and License Agr..
PU
06/28INCYTE : New Global Cholangiocarcinoma Alliance announces founding supporters
AQ
06/17INCYTE : Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in..
AQ
06/15INCYTE : Summary ToggleIncyte Announces Positive Results from a Phase 2 Study of..
PU
06/15INCYTE : Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in..
BU
06/04INCYTE : Summary ToggleIncyte Announces First Patient Treated in Phase 3 Clinica..
PU
06/04INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatini..
BU
06/04INCYTE : New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results ..
AQ
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Biotechnology & Medical Research - NEC
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 89,29  $
Last Close Price 80,54  $
Spread / Highest target 40,3%
Spread / Average Target 10,9%
Spread / Lowest Target -6,88%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION26.66%17 271
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP31.57%25 623
CELLTRION, INC.--.--%20 071
EXACT SCIENCES CORPORATION85.26%14 835
SEATTLE GENETICS, INC.32.49%12 140